secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001171843-23-005107
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q2 revenue rises 12% to $44.3M; raises FY2023 guidance floor to $159.5M
-----------------------------------------------------------------------------

- Q2 revenue $44.3M (+12% YoY); net loss ($0.19)/share; adjusted EPS $0.06 vs ($0.12) prior year.
- OA Pain Mgmt rev +22% to $29.3M; Joint Preservation & Restoration +5% to $12.7M.
- FY2023 rev guidance raised: $159.5M-$163M (was $158M-$163M), representing 2-4% growth.
- Hyalofast Phase III fully enrolled; PMA submission begins 2024; Cingal ongoing FDA discussions after Type-C meeting.
- RevoMotion reverse shoulder full market launch accelerated to Sept 2023; Integrity rotator cuff patch 2024 launch on track.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184323005107/0001171843-23-005107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184323005107/f8k_080823.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-005107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer